Pepgen INC 8-K filings

PepGen reported its Q1 2024 financial results, highlighted clinical trial progress, and announced a cash runway extension into 2026.

PepGen Inc. has updated its bylaws to incorporate universal proxy rules, revise advance notice procedures, and clarify meeting conduct, effective March 15, 2024.

PepGen has been granted both Orphan Drug and Rare Pediatric Disease Designations by the FDA for PGN-EDO51, a treatment for Duchenne muscular dystrophy.

PepGen reported its 2023 financial results, highlighted clinical trial advancements, and announced an $80 million follow-on offering, extending its cash runway into 2026.

PepGen has received clearance from the UK's MHRA to begin a Phase 2 clinical trial for its PGN-EDO51 therapy for Duchenne Muscular Dystrophy.

PepGen has been granted Fast Track designation by the FDA for its investigational drug PGN-EDODM1, aimed at treating myotonic dystrophy type 1 (DM1).

PepGen Inc. has priced a public offering of 7,530,000 shares of common stock at $10.635 per share, expecting to raise approximately $80.1 million before expenses.

PepGen Inc. has announced the appointment of Mary Beth DeLena as General Counsel and Secretary, expanding its executive team.